Company Description
AlphaTON Capital Corp., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.
Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor.
The company was formerly known as Portage Biotech Inc. and changed its name to AlphaTON Capital Corp. in September 2025.
AlphaTON Capital Corp. is based in Tortola, British Virgin Islands.
| Country | British Virgin Islands |
| Founded | 1973 |
| Industry | Asset Management |
| Sector | Financials |
| Employees | 4 |
| CEO | Brittany Kaiser |
Contact Details
Address: Clarence Thomas Building, P.O. Box 4649 Tortola, VG1110 British Virgin Islands | |
| Phone | 302 219 5556 |
| Website | alphatoncapital.com |
Stock Details
| Ticker Symbol | ATON |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001095435 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter Molloy | Chief Executive Officer of Cyncado Therapeutics Inc. |
| Brittany Kaiser | Chief Executive Officer and Director |
| Eun-Jae Park CPA | Chief Financial Officer |
| Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer |
| Adam Melero | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2025 | 424B3 | Prospectus |
| Sep 25, 2025 | 424B3 | Prospectus |
| Sep 25, 2025 | 6-K | Report of foreign issuer |
| Sep 23, 2025 | 6-K | Report of foreign issuer |
| Sep 17, 2025 | D | Notice of Exempt Offering of Securities |
| Sep 5, 2025 | 424B3 | Prospectus |
| Sep 4, 2025 | 6-K | Report of foreign issuer |
| Sep 3, 2025 | 424B5 | Filing |
| Sep 3, 2025 | 424B3 | Prospectus |
| Sep 3, 2025 | 6-K | Report of foreign issuer |